| President Donald Trump's recent executive order on prescription drug costs includes several provisions, including efforts to reduce insulin prices and rein in pharmacy benefit managers. However, there is one measure that has made some patient advocates upset. The executive order includes a potential change to the Medicare Drug Price Negotiation Program that would delay when certain drugs can be selected for negotiation. Currently, drugs can only be selected for negotiation if they are brand-name drugs or biological products without generic or biosimilar equivalents. Small molecule drugs have to be seven years past their FDA approval or licensure date, while biologics have to be 11 years past this date. The Trump administration's executive order could give small molecule drugs an extra four years before they're eligible to be selected for the negotiation program. | 
No comments